<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02571283</url>
  </required_header>
  <id_info>
    <org_study_id>14.1276</org_study_id>
    <nct_id>NCT02571283</nct_id>
  </id_info>
  <brief_title>Peri-articular Injection Utilizing a Pain Cocktail With and Without Exparel</brief_title>
  <official_title>A Randomized, Prospective Trial Comparing Peri-articular Injection Utilizing a Pain Cocktail With and Without Exparel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arthroplasty Foundation, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized control study will be conducted to compare postoperative pain
      control in a series of patients treated with either:

        1. a local cocktail.

        2. a local cocktail plus Exparel.

        3. marcaine plus Exparel prior to wound closure following knee arthroplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As an alternative to the various injection cocktails, Exparel, a liposomal-coated
      bupivicaine, was introduced as a long-acting form of bupivicaine, a local anesthetic. This
      new technology has been utilized by numerous orthopedic joint surgeons. Since its
      introduction there have been studies showing varying results in terms of postoperative pain
      control.

      Therefore, it is our purpose to conduct a prospective, randomized control study to compare
      postoperative pain control in a series of patients treated with either:

        1. a local cocktail.

        2. a local cocktail plus Exparel.

        3. marcaine plus Exparel prior to wound closure following knee arthroplasty.

      METHODOLOGY

      Subjects will be randomized preoperatively into three different groups on total knee subjects
      done at three different facilities. This study is single blinded study. The visual pain scale
      from 1-10 will be used to determine pain control at 3, 12, 24, and 48 hour time intervals
      postoperatively. Postoperative narcotic use will also be monitored at the same time
      intervals.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI decided to focus on more current topics of interest.
  </why_stopped>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The visual pain scale from 1-10 will be used to determine changes in pain control at 3, 12, 24, and 48 hour time intervals postoperatively.</measure>
    <time_frame>Pain control intervals will be assessed at 3, 12, 24, and 48 hour time intervals postoperatively.</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <condition>Pain Management</condition>
  <arm_group>
    <arm_group_label>Randomized Group A [Cocktail Injection]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COCKTAIL INJECTION:
Cocktail Injection Consists of:
Ropivacaine (Brand Name: Naropin) 5 mg/ml (49.25 ml) Ketorolac (Brand Names: Toradol, Sprix, Acuvail, Acular) 30 mg/ml (1 ml) Epinephrine (Brand Names: EpiPen, Adrenaclick, Medihaler-Epi, Twinject) 1 mg/ml (0.5 ml) Clonidine (Brand Names: Kapvay, Catapres, Duraclon, Nexiclon) 0.1 mg/ml (0.08 mg = 0.8 ml) Normal Saline added to total of 100 cc Dosage Form: Injection Dosage: See above Frequency: Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Group B [Cocktail Injection Plus Exparel]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COCKTAIL INJECTION PLUS EXPAREL:
Cocktail Injection Consists of:
Ropivacaine (Brand Name: Naropin) 5 mg/ml (49.25 ml) Ketorolac (Brand Names: Toradol, Sprix, Acuvail, Acular) 30 mg/ml (1 ml) Epinephrine (Brand Names: EpiPen, Adrenaclick, Medihaler-Epi, Twinject) 1 mg/ml (0.5 ml) Clonidine (Brand Names: Kapvay, Catapres, Duraclon, Nexiclon) 0.1mg/ml (0.08 mg = 0.8 ml) Normal Saline added to total of 100 cc Dosage Form: Injection Dosage: See above Frequency: Single dose
Bupivacaine Liposome (Brand Name: Exparel) Dosage Form: Injection Dosage: 20 ml Single use vial, 1.3% (13.3 mg/ml) Frequency: Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Group C [Marcaine Plus Exparel]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MARCAINE PLUS EXPAREL:
Bupivacaine Hydrochloride (Brand Name: Marcaine, Sensorcaine) Dosage Form: Injection Dosage: 3 ml vial, 0.5% solution Frequency: Single dose
Bupivacaine Liposome (Brand Name: Exparel) Dosage Form: Injection Dosage: 20 ml Single use vial, 1.3% (13.3 mg/ml) Frequency: Single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocktail</intervention_name>
    <description>Administered as a single dose injection.</description>
    <arm_group_label>Randomized Group A [Cocktail Injection]</arm_group_label>
    <arm_group_label>Randomized Group B [Cocktail Injection Plus Exparel]</arm_group_label>
    <other_name>Naropin</other_name>
    <other_name>Toradol</other_name>
    <other_name>Sprix</other_name>
    <other_name>Acuvail</other_name>
    <other_name>Acular</other_name>
    <other_name>EpiPen</other_name>
    <other_name>Adrenaclick</other_name>
    <other_name>Medihaler-Epi</other_name>
    <other_name>Twinject</other_name>
    <other_name>Kapvay</other_name>
    <other_name>Catapres</other_name>
    <other_name>Duraclon</other_name>
    <other_name>Nexiclon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <description>Administered 20 minutes+ before additional medications.</description>
    <arm_group_label>Randomized Group B [Cocktail Injection Plus Exparel]</arm_group_label>
    <arm_group_label>Randomized Group C [Marcaine Plus Exparel]</arm_group_label>
    <other_name>Bupivacaine Liposome</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marcaine</intervention_name>
    <description>Administered 20 minutes or more after Exparel is administered.</description>
    <arm_group_label>Randomized Group C [Marcaine Plus Exparel]</arm_group_label>
    <other_name>Bupivacaine Hydrochloride</other_name>
    <other_name>Bupivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Institutional Review Board (IRB) review has been conducted and approval of the study
             has been obtained

          -  The subject underwent a primary total knee replacement under adductor canal block with
             general anesthesia

        Exclusion Criteria:

          -  The subject is a minor

          -  The subject is on chronic narcotics

          -  The subject has an indwelling pain pump

          -  The subject is having a knee revision surgery

          -  The subject is having a partial knee replacement

          -  The subject has a history of sepsis in a previously replaced joint

          -  The subject has back pain

          -  The subject has radicular pain

          -  The subject suffers from depression

          -  The subject has fibromyalgia

          -  The subject is currently involved in any personal injury litigation, medical-legal, or
             worker's compensation claims
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total Knee Arthroplasty</keyword>
  <keyword>Total Knee Replacement</keyword>
  <keyword>Exparel</keyword>
  <keyword>Cocktail Injection</keyword>
  <keyword>Pain Management</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

